The Experts below are selected from a list of 13065 Experts worldwide ranked by ideXlab platform
Hilton Whittle - One of the best experts on this subject based on the ideXlab platform.
-
Randomized Trials Comparing Inactivated Vaccine After Medium- or High-titer Measles Vaccine With Standard Titer Measles Vaccine After Inactivated Vaccine: A Meta-analysis.
The Pediatric infectious disease journal, 2016Co-Authors: Peter Aaby, Henrik Ravn, Christine Stabell Benn, Amabelia Rodrigues, Badara Samb, Salah A. Ibrahim, Michael Libman, Hilton WhittleAbstract:: Observational studies have suggested that girls have higher mortality if their most recent immunization is an Inactivated Vaccine rather than a live Vaccine. We therefore reanalyzed five randomized trials of early measles Vaccine (MV) in which it was possible to compare an Inactivated Vaccines (after medium or high titer MV) and a live standard titer MV (after an initial Inactivated Vaccine). : The trials were conducted in Sudan, Senegal, The Gambia and Guinea-Bissau. The intervention group received live medium or high titer MV from 4-5 months, and then an Inactivated Vaccine from 9-10 months of age; the control children received Inactivated Vaccine/placebo from 4-5 months, and standard titer MV from 9-10 months of age. We compared mortality from 9 months until end of study at 3-5 years of age for children who received Inactivated Vaccine (after medium or high titer MV) and standard titer MV (after Inactivated Vaccine), respectively. The original data sets were analyzed using a Cox proportional hazards model stratified by trial. : The mortality rate ratio (MRR) was 1.38 (95% CI: 1.05-1.83) after an Inactivated Vaccine (after medium or high titer MV) compared with a standard titer MV (after Inactivated Vaccine). Girls had a MRR of 1.89 (1.27-2.80) whereas there was no effect for boys, the sex-differential effect being significant (p=0.02). Excluding measles cases did not alter these conclusions, the MRR after Inactivated Vaccines (after medium or high titer MV) being 1.40 (1.06-1.86) higher overall and 1.92 (1.29-2.86) for girls. Control for variations in national immunization schedules for other Vaccines did not modify these results. : After 9 months of age, all children had been immunized against measles, and mortality in girls was higher when they had received Inactivated Vaccines (after medium or high titer MV) rather than live standard titer MV (after an Inactivated Vaccine).
Peter Aaby - One of the best experts on this subject based on the ideXlab platform.
-
Randomized Trials Comparing Inactivated Vaccine After Medium- or High-titer Measles Vaccine With Standard Titer Measles Vaccine After Inactivated Vaccine: A Meta-analysis.
The Pediatric infectious disease journal, 2016Co-Authors: Peter Aaby, Henrik Ravn, Christine Stabell Benn, Amabelia Rodrigues, Badara Samb, Salah A. Ibrahim, Michael Libman, Hilton WhittleAbstract:: Observational studies have suggested that girls have higher mortality if their most recent immunization is an Inactivated Vaccine rather than a live Vaccine. We therefore reanalyzed five randomized trials of early measles Vaccine (MV) in which it was possible to compare an Inactivated Vaccines (after medium or high titer MV) and a live standard titer MV (after an initial Inactivated Vaccine). : The trials were conducted in Sudan, Senegal, The Gambia and Guinea-Bissau. The intervention group received live medium or high titer MV from 4-5 months, and then an Inactivated Vaccine from 9-10 months of age; the control children received Inactivated Vaccine/placebo from 4-5 months, and standard titer MV from 9-10 months of age. We compared mortality from 9 months until end of study at 3-5 years of age for children who received Inactivated Vaccine (after medium or high titer MV) and standard titer MV (after Inactivated Vaccine), respectively. The original data sets were analyzed using a Cox proportional hazards model stratified by trial. : The mortality rate ratio (MRR) was 1.38 (95% CI: 1.05-1.83) after an Inactivated Vaccine (after medium or high titer MV) compared with a standard titer MV (after Inactivated Vaccine). Girls had a MRR of 1.89 (1.27-2.80) whereas there was no effect for boys, the sex-differential effect being significant (p=0.02). Excluding measles cases did not alter these conclusions, the MRR after Inactivated Vaccines (after medium or high titer MV) being 1.40 (1.06-1.86) higher overall and 1.92 (1.29-2.86) for girls. Control for variations in national immunization schedules for other Vaccines did not modify these results. : After 9 months of age, all children had been immunized against measles, and mortality in girls was higher when they had received Inactivated Vaccines (after medium or high titer MV) rather than live standard titer MV (after an Inactivated Vaccine).
Xiao Fang Yu - One of the best experts on this subject based on the ideXlab platform.
-
optimization and characterization of candidate strain for coxsackievirus a16 Inactivated Vaccine
Viruses, 2015Co-Authors: Jingliang Li, Junliang Chang, Jiaxin Yang, Wenyan Zhang, Xiao Fang YuAbstract:Coxsackievirus A16 (CA16) and enterovirus 71 (EV71), both of which can cause hand, foot and mouth disease (HFMD), are responsible for large epidemics in Asian and Pacific areas. Although Inactivated EV71 Vaccines have completed testing in phase III clinical trials in Mainland China, CA16 Vaccines are still under development. A Vero cell-based Inactivated CA16 Vaccine was developed by our group. Screening identified a CA16 Vaccine strain (CC024) isolated from HFMD patients, which had broad cross-protective abilities and satisfied all requirements for Vaccine production. Identification of the biological characteristics showed that the CA16CC024 strain had the highest titer (107.5 CCID50/mL) in Vero cells, which would benefit the development of an EV71/CA16 divalent Vaccine. A potential Vaccine manufacturing process was established, including the selection of optimal time for virus harvesting, membrane for diafiltration and concentration, gel-filtration chromatography for the down-stream virus purification and virus inactivation method. Altogether, the analyses suggested that the CC-16, a limiting dilution clone of the CC024 strain, with good genetic stability, high titer and broad-spectrum immunogenicity, would be the best candidate strain for a CA16 Inactivated Vaccine. Therefore, our study provides valuable information for the development of a Vero cell-based CA16 or EV71-CA16 divalent Inactivated Vaccine.
Wang Bi-cheng - One of the best experts on this subject based on the ideXlab platform.
-
Study on Bicombinant Propolis Inactivated Vaccine of Rabbit Heamorrhagic Disease and Pasteurellosis
Journal of Animal Science and Veterinary Medicine, 2010Co-Authors: Wang Bi-chengAbstract:Rabbit hemorrhagic disease virulent strain GMH881 and pasteurellosis strain C51-17 were selected as good immunogenicity,bicombinant inactivacted Vaccine were developed successfully.To ascertain the safety and immune effects of bicombintaint invactivated Vaccine,test was carried out on immune dosage,potency,immune duration and storage life.Immune dose of the bicombintaint Inactivated Vaccines was 1.0 mL,the immune protection rate of bicombintaint invactivated Vaccine against RHD was 100 % on the 5th day vaccination,the immune protection rate of bicombintaint invactivated Vaccine against Pm was over 80 % on the 7th day after vaccination.To supervise the level of RHDV through HI method,the results showed that the titers of bicombinant Inactivated caccine were 22.75 after 7 d of injection,and the antibody effect could reach very high level after 15th day,which could reach peak level(28.0) on day 30,antibody effect level of bicombinant Inactivated Vaccine was 27.0~25.5 during 60 ～ 120 days,on day 180 it slightly reduced to 25.25.Four and six month after vaccination,the protection rate of the bicombintaint Inactivated Vaccines was 100% against rabbit haemorrhagic disease with injecting pathogens,more than 70% against pasteurellosis with 2 MLD of the pasteurlla multocida strain C51-17 on 6th month.The bicombintaint invactivated Vaccine can provide effective protection when it was stored at 4 ～ 8℃ for 12 months,at 25 ℃ for 6 months.
-
Storage Life of the Bicombinant Propolis Inactivated Vaccine of Rabbit Hemorrhagic Disease and Pasteurellosis
Chinese Journal of Rabbit Farming, 2008Co-Authors: Wang Bi-chengAbstract:Two batches of the bicombinant propolis Inactivated Vaccine of rabbit hemorrhagic disease and pasteurellosis were taken out after the storage for 6 months and 12 months in 4~8℃ and room temperature, injecting pathogeny at different time after immunization. The results shows, protection rate was 100% against rabbit haemorrhagic disease after the storage life of 6 and 12 months in 4~8℃ and room temperature, 100% against pasteurellosis after the storage life of 6 months and 90% after the storage life of 12 month in 4～8℃; 80% against pasteurellosis after the storage life of 6 months, 70% after the storage life of 12 months at room temperature. The storage life confirmed is 12 months in 4～8℃ or 6 months at room temperature.
-
Observation of Immunization Effect and development of Bicombinant Inactivated Vaccine of Rabbit Heamorrhagic Disease and Pasteurellosis
Journal of Animal Science and Veterinary Medicine, 2008Co-Authors: Wang Bi-chengAbstract:It was suitable for this region that Rabbit hemorrhagic disease virulent strain and pasteurellosis strain were good immunogenicity,bicombinant propolis Inactivated Vaccine and bicombinant Inactivated caccine were developed successfully.To supervise the level of RHDV through serological method,the result showed that the titers of bicombinant Inactivated caccine and bicombinant propois Inactivated Vaccine were 5.0 log2,5.5log2,5.6log2,6.25log2,8.0log2 and 5.0log2,5.5log2,5.6log2,9.25log2,11.0log2 after 7 d,10 d,15 d,20 d,30 d of injection respectively.Propois could produce could obviously improve antibody titer and enhange immune effect.
Lichun Wang - One of the best experts on this subject based on the ideXlab platform.
-
Immunoprotection elicited by an enterovirus type 71 experimental Inactivated Vaccine in mice and rhesus monkeys.
Vaccine, 2011Co-Authors: Chenghong Dong, Longding Liu, Hongling Zhao, Jingjing Wang, Yun Liao, Xuemei Zhang, Yan Liang, Lichun WangAbstract:A number of commonly recognized public health issues are associated with EV71 infection, including the induction of severe cases of hand-foot-and-mouth disease (HFMD). Because of such issues, research and development of EV71 Vaccine candidates is of growing importance. In the present study, an experimental EV71 Inactivated Vaccine was prepared, and its corresponding immunogenicity was analyzed. The immune responses and immunoprotective effect induced by the Vaccine in mice and rhesus monkeys are described, and the two animal models are compared to evaluate the potential of assessing the Inactivated Vaccine's immunogenicity in these two species. In addition to assessing the Vaccine's efficacy in mice, our data further elucidate the significance and value of assessing the immunogenicity and immunoprotection of Vaccine candidates in rhesus monkeys by relying on a range of analyses, including pathological, etiological and lethal challenge analyses.
